יצחק ויץ
מאמרים נבחרים

Witz IP and Izraely S. Introduction to the Tumor Microenvironment. In: Biomaterials Science Series No. 14; Biomaterial Based Approaches to Study the Tumour Microenvironment. Jessica O. Winter JO, Rao SS Editors. Royal Society of Chemistry. 11–29, 2023.
Witz IP and Izraely S. The microenvironment of Site-specific Metastasis. In: Cancer Metastasis Through the Lymphovascular System. Leong SP, Nathanson D, Zager JS Editors. Springer Nature Switzerland, 107–115, 2022.
Witz IP. The cross talk between cancer cells and their microenvironments. Biochem Biophys Res Commun. 633:59–60, 2022.
Leong SP, Witz IP, Sagi-Assif O, Izraely S, Sleeman J, Piening B, Fox BA, Bifulco CB, Martini R, Newman L, Davis M, Sanders LM, Haussler D, Vaske OM, Witte M. Cancer microenvironment and genomics: evolution in process. Clin Exp Metastasis. 39:85–99, 2022.
De Las Rivas J, Brozovic A, Izraely S, Casas-Pais A, Witz IP, Figueroa A. Cancer drug resistance induced by EMT: novel therapeutic strategies. Arch Toxicol. 95:2279–2297, 2021.
Izraely S, Witz IP. Site-specific metastasis: A cooperation between cancer cells and the metastatic microenvironment. Int J Cancer.148:1308–1322, 2021.
Maman S, Witz IP. A history of exploring cancer in context. Nat Rev Cancer. 18:359–376, 2018.
Klein-Goldberg A, Maman S, Witz IP. The role played by the microenvironment in site-specific metastasis. Cancer Lett. 352:54-58, 2014.
Witz IP. Tumor-microenvironment interactions: dangerous liaisons. Adv Cancer Res. 100:203-29, 2008.
Witz IP. The selectin-selectin ligand axis in tumor progression. Cancer Metastasis Rev, 27:19–30. 2008.
Witz IP. Yin-yang activities and vicious cycles in the tumor microenvironment. Cancer Res, 68:9–13. 2008.
Witz IP, Levy-Nissenbaum O. The tumor microenvironment in the post-PAGET era. Cancer Lett. 8. 242:1–10, 2006.
Eshel R, Neumark E, Sagi-Assif O, Witz IP. Receptors involved in microenvironment-driven molecular evolution of cancer cells. Semin Cancer Biol. 12:139-47. 2002.
Witz IP. Presence and functions of immune components in the tumor microenvironment. Adv Exp Med Biol. 495:317-24. 2001.
Sagi-Assif O, Douer D, Witz IP. Cytokine network imbalances in plasmacytoma – regressor mice. Curr Top Microbiol Immunol. 246:395–401. 1999.
Ran M, Langer AB, Eliassi I, Gohar O, Gonen B, Gradsztajn S, Fridman WH, Teillaud JL, Witz IP. Possibilities of interference with the immune system of tumor bearers by non-lymphoid Fc gamma RII expressing tumor cells. Immunobiology. 185:415-25, 1992.
Witz IP, Ran M. FcR may function as a progression factor of nonlymphoid tumors. Immunol Res. 11:283-95, 1992.
Witz IP, Agassy-Cahalon L. Do naturally occurring antibodies play a role in the progression and proliferation of tumor cells? Int Rev Immunol. 3:133-45, 1988.
Ran M, Witz IP. FcR derived from without the immune system—a potential escape mechanism for cells propagating in a hostile immunological environment. Contrib Gynecol Obstet. 14:83-89, 1985.
Witz IP, Meyer G. Membrane antigens associated with infection, transformation, and tumorigenesis by polyoma virus. Cancer Immunol Immunother. 17:147-153, 1984.
Witz IP. Tumor-bound immunoglobulins: in situ expressions of humoral immunity. Adv Cancer Res. 25:95–148, 1977.
Witz IP. The biological significance of tumor-bound immunoglobulins. Curr Top Microbiol Immunol. 61:151-71,1973.